Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading ->
Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading ->
A network of life sciences organisations working together to address antibacterial resistance worldwide has expanded to now include 10 top organisations from six countries, according to CARB-X (Combating Antibiotic Resistant Bacteria), a US-based partnership investing hundreds of millions of dollars in R&D for antibacterial resistance over 5 years. Continue reading ->
Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading ->
Geneva-based Gavi, the Vaccine Alliance, today announced the start of a major two-week campaign to vaccinate hundreds of thousands of people in Harare, Zimbabwe against typhoid, after an outbreak there. The campaign will be the first in Africa to use a new typhoid vaccine that can be administered to young children and is long-lasting. Nearly 2,000 cases of typhoid have been reported since a second wave of outbreak arose in September, Gavi said. Continue reading ->